drugset
drugset / Trial / NCT03521297

Probiotics in PBC Patients of Poor Response to UDCA

NCT03521297 ↗

Phase 2 Unknown 60 enrolled Sun Yat-sen University
RandomizedParallel-groupSingle-blindTreatment

Summary

The safety and efficacy of probiotics in primary biliary cholangitis (PBC) patients with poor ursodeoxycholic acid (UDCA) response.

Timeline

Start
2020-01-20
Primary completion
2021-01-31
Completion
2021-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Micro V Probiotics Unknown — Oral

Indications

primary biliary cholangitis